跳至主要内容
临床试验/NCT06214039
NCT06214039终止不适用

Virtual Reality Based Cognitive Behavioral Therapy for Public Speaking Anxiety

Vilnius University1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2024年2月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
37
试验地点
1
主要终点
Public Speaking Anxiety Scale (PSAS), (Bartholomay & Houlihan, 2016).

研究概览

简要总结

This study aims to examine the efficacy of exposure using virtual reality (VR) for public speaking anxiety in young adults in two treatment arms: a one-session VR exposure therapy with a 4-week online transition intervention versus a three-session VR exposure therapy with a 4-week online transition intervention. Previous studies have demonstrated that one-session therapy (OST) is comparable to prolonged exposure-based therapies in terms of effectively reducing public speaking anxiety. Moreover, VR offers many benefits compared to in-person exposure, namely the ability to produce anxiety-evoking stimuli without having to leave the therapist's room. However, OST VR exposure has not been directly compared to prolonged VR exposure and not for public speaking anxiety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 30 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • aged 18-30 and pursuing higher education;
  • experiencing a significant level of public speaking anxiety (60+ on PSAS);
  • able to use a computer and have access to the internet for the duration of the study;
  • able to understand, write and speak in Lithuanian;
  • available to participate in one or three in-person intervention sessions and can devote the time to participate in a 4-week online program following the intervention sessions.

排除标准

  • a history of seizures or a history of epilepsy;
  • other significant medical conditions that would prevent them from participating in the program;
  • high levels of depression (Patient Health Questionnaire-9 rating of 15 and above and mentions of suicidal ideation) or other significant psychiatric conditions that would interfere with participation in the program;
  • a tendency to have extreme seasickness reactions or a history of adverse physical reactions to virtual reality experiences or difficulty with or lack of stereoscopic vision;
  • current involvement in other psychological interventions such as psychological counseling or psychotherapy;
  • use of psychoactive drugs, unless stable for three months;
  • current participation in other programs aimed at reducing public speaking anxiety.

研究组 & 干预措施

One session therapy

Active Comparator

One session exposure therapy followed by 4 weeks of internet-delivered self-help with therapist support on demand

干预措施: Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety (Behavioral)

One session therapy - divided into 3

Experimental

Three session exposure therapy followed by 4 weeks of internet-delivered self-help with therapist support on demand

干预措施: Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety (Behavioral)

结局指标

主要结局

Public Speaking Anxiety Scale (PSAS), (Bartholomay & Houlihan, 2016).

时间窗: Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment

Canonical total score will be used. Measure is self-rated, online. The scale consists of 17 self-report statements measured on a Likert-type scale ranging from 1 "not at all", to 5 "extremely". A higher score indicates higher levels of experienced public speaking anxiety.

Public Speaking Anxiety Scale (PSAS).

时间窗: Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment

Canonical total score will be used. Measure is self-rated, online. The scale consists of 17 self-report statements measured on a Likert-type scale ranging from 1 "not at all", to 5 "extremely". A higher score indicates higher levels of experienced public speaking anxiety.

次要结局

  • Patient health questionnaire - 9 (PHQ-9), (Spitzer et al., 1999)(Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment)
  • Brief Fear of Negative Evaluation Scale (BFNE), (Leary, 1983)(Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment)
  • Igroup Presence Questionnaire (IPQ)(Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment)
  • Liebowitz Social Anxiety Scale - Self-Report (LSAS-SR), (Liebowitz, 2003; Rytwinski et al., 2009)(Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment)
  • Liebowitz Social Anxiety Scale - Self-Report (LSAS-SR)(Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment)
  • Brief Fear of Negative Evaluation Scale (BFNE)(Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jonas Eimontas

Associate Professor, Senior Research Fellow

Vilnius University

研究点 (1)

Loading locations...

相似试验